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Retroperitoneal  ﬁbrosis  (RPF)  is an  uncommon  disease  characterized  by  a ﬁbrous  reaction  that  takes  place
in  the peri-aortic  retroperitoneum  and  often  entraps  the  ureters  causing  obstructive  uropathy.  RPF  is  idio-
pathic  in the majority  of  cases,  but  can  also  be secondary  to malignancies,  infections,  drugs,  radiotherapy,
and  rare  histiocytic  disorders  such  as  Erdheim–Chester  disease.  Idiopathic  RPF  is  an immune-mediated
disease,  which  can  either  be  isolated,  associated  with  other  autoimmune  diseases,  or  arise  in the  context
of  a multifocal  ﬁbro-inﬂammatory  disorder  recently  renamed  as IgG4-related  disease.  The  differentialecondary retroperitoneal ﬁbrosis
diagnosis  between  idiopathic,  IgG4-related  and  secondary  RPF  is  crucial,  essentially  because  the  thera-
peutic  approaches  – especially  of  idiopathic  vs. secondary  RPF  – can  be dramatically  different.  This  review
focuses  on  the  clinical,  laboratory  and  imaging  features  of the  different  RPF  forms,  and  also  provides  an
overview  of the available  treatment  options.
©  2014 Published  by Elsevier  Masson  SAS  on  behalf  of  the  Société  nationale  française  de  médecine
interne (SNFMI). Este é um artigo Open Access sob a licença de CC BY-NC-ND. Introduction
Retroperitoneal ﬁbrosis (RPF) comprises a spectrum of rare
iseases hallmarked by the presence of an aberrant ﬁbro-
nﬂammatory tissue that usually develops around the infra-renal
ortion of the abdominal aorta and the iliac arteries and frequently
ntraps neighbouring structures such as the ureters and the infe-
ior vena cava [1]. Retroperitoneal ﬁbrosis may  develop around an
ndilated or a dilated aorta, therefore “non-aneurysmal forms” and
peri-aneurysmal forms” of RPF can be distinguished.
Idiopathic RPF accounts for more than two thirds of the cases of
PF, the remaining third being secondary to other causes such as
eoplasms, infections, trauma, radiotherapy, surgery, and intake of
rugs [2]. The diagnosis is generally obtained by means of appro-
riate imaging studies (e.g., abdomen computed tomography, or
agnetic resonance imaging) but, in patients presenting with a
ewly diagnosed RPF, it is mandatory to exclude malignancy with
n age-appropriate cancer screening and, when there are clinical
nd radiological signs of underlying malignancies or infections, a
etroperitoneal biopsy should be performed.
∗ Corresponding author. Unità Operativa di Nefrologia, Azienda Ospedaliero-
niversitaria  di Parma, Via Gramsci 14, 43126 Parma, Italy.
E-mail  address: augusto.vaglio@virgilio.it (A. Vaglio).
http://dx.doi.org/10.1016/j.revmed.2014.10.008
248-8663 © 2014 Published by Elsevier Masson SAS on behalf of the Société nationale fr
Este é um artigo Open Access sob a licença de CC BY-NC-NDThere are no standardized criteria to classify idiopathic RPF, but
this is currently included in the spectrum of chronic periaortitis (CP)
together with peri-aneurysmal RPF and inﬂammatory abdominal
aortic aneurysms, as all of these forms have common histological
features and a similar clinical presentation; recently, it has been
proposed that CP is a form of large vessel vasculitis, especially in
cases that also show thoracic aorta involvement [3]. Furthermore,
idiopathic RPF (or CP) may  be isolated or may develop in the context
of a systemic immune-mediated disease.
Some authors argued that idiopathic RPF is part of the spec-
trum of immunoglobulin G4 (IgG4)-related disease (IgG4-RD) an
immune-mediated disorder that may  affect different organs (e.g.,
pancreas, gallbladder, salivary glands) and that is histologically
hallmarked by a lymphoplasmacytic inﬁltrate rich in IgG4-bearing
plasma cells, storiform ﬁbrosis, tissue eosinophilia and obliterative
phlebitis, and also characterised by increased levels of serum IgG4
in a signiﬁcant proportion of cases [4,5]; some cases of idiopathic
RPF have indeed such histological and clinical features, and can
therefore be classiﬁed as being IgG4-related [6], although the exact
proportion of IgG4-related out of the total number of idiopathic RPF
cases is still unclear.
This  review will focus on the clinical features of idiopathic RPF
and will explore how to differentiate this entity from other diseases
affecting the retroperitoneal space that can have a similar clinical
presentation.
ançaise de médecine interne (SNFMI).
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. Epidemiology
There are limited data about the epidemiology of this rare dis-
ase. One study from Finland showed an incidence of 0.1/100,000
nhabitants/year, and a prevalence of 1.4/100,000 inhabitants,
hereas a more recent analysis performed in the Netherlands
eported a 13-fold higher incidence, of 1.3/100,000 inhabi-
ants/year [7,8]. This could mean that, with improved knowledge
f the disease and greater accuracy of imaging techniques, the
ncidence of idiopathic RPF might turn out to be signiﬁcantly
igher than previously thought. The mean age at presentation is
0–60 years and there is a male predominance (male/female ratio
:1 to 3:1). Pediatric cases are rare, with up to 30 patients described
n the literature [9]. No clear data are available concerning the
revalence and incidence of secondary RPF [10].
. Etiopathogenesis
Different mechanisms have been proposed to explain the patho-
enesis of idiopathic RPF.
An  early theory, proposed in the mid-1980s by Parums and
itchinson, deﬁned idiopathic RPF as a complication of advanced
ortic atherosclerosis. These authors postulated that the ﬁbro-
nﬂammatory tissue may  result from an initial processing of
xidized lipids by plaque macrophages, which migrate from the
ntima-media to the adventitia (especially when there is medial
hinning as it occurs in atherosclerosis), where they present such
ipids to lymphocytes and plasma cells, thus triggering adventi-
ial and peri-adventitial inﬂammation and ﬁbrosis [11]. However,
his theory contrasts with the clinical evidence of idiopathic RPF in
atients who do not suffer from atherosclerosis or have suffered no
ajor cardiovascular events. In addition, this view cannot explain
he complex systemic nature of idiopathic RPF, which in many
ases presents with systemic symptoms, raised levels of inﬂam-
atory markers and concomitant autoimmune diseases involving
ther organs (e.g., Hashimoto’s thyroiditis, small-vessel vasculitis,
soriasis and Sjögren’s syndrome) [12,13].
Idiopathic RPF may  instead be a manifestation of a systemic
utoimmune disease, and may  arise as a primary aortitis that
ubsequently elicits a peri-aortic ﬁbro-inﬂammatory response. In
eeping with this hypothesis is the observation that inﬂammation
redominates in the adventitia, where vasculitis of vasa vasorum
ogether with lymphoid follicles with germinal centers can also
e found. Studies conducted on aortic biopsies showed the pres-
nce of gene transcripts of interferon- (IFN-), interleukin-1
IL-1), IL-2 and IL-4, suggesting lymphocytic activation [1,3,14].
oreover, it has been reported that idiopathic RPF often affects
ther vascular segments (e.g., thoracic aorta, mesenteric arteries)
hat are usually spared by atherosclerosis [3,15]. Clinical ﬁnd-
ngs such as the presence of systemic symptoms, the association
ith other autoimmune disorders as well as the good response to
mmunosuppressive therapies ﬁt this systemic immune-mediated
heory.
Multiple factors may  contribute to this process. Martorana et al.
16] demonstrated a strong association between idiopathic RPF and
LA-DRB1*03, an allele linked to many autoimmune conditions
uch as type 1 diabetes, myasthenia gravis and autoimmune thy-
oiditis. A recent study also described an increased susceptibility to
evelop idiopathic RPF, especially its aneurysmal form, in patients
arrying the delta 32 (32) polymorphism of the CC-chemokine
eceptor 5 (CCR5) gene [17]. CCR5 is expressed on many immune
ells, particularly Th1 cells, and acts by binding several chemokines,
ncluding RANTES, MIP-1 and MIP-1. The CCR532 polymor-
hism creates a truncated, nonfunctional receptor and probably
hifts the immune response toward a Th2 pattern.cine interne 36 (2015) 15–21
Environmental factors also play a role in the susceptibility to
idiopathic RPF. Occupational asbestos exposure and tobacco smoke
are two  important risk factors for the development of idiopathic
RPF [7]. Goldoni et al. [18] have recently shown that the interaction
between these two  factors has a multiplicative effect rather than
just an additive one: this translates into a markedly increased risk of
developing idiopathic RPF (with an odds ratio > 10) when a patient
is exposed to both factors [18].
The role of microbial agents as disease triggers is still elusive
[19,20].
A broad range of factors may  cause secondary forms of RPF,
including drugs, infections, external-beam radiation and malignan-
cies.
With regards to drugs, the most frequent associations are
between RPF and derivatives of ergot alkaloids (e.g., methysergide,
ergotamine), or with dopamine agonists (e.g., pergolide, methyl-
dopa). Methysergide and the other ergotamine-derived agents
increase the levels of endogenous serotonin and this has been
suggested to lead to ﬁbrotic reactions through proliferation of
myoﬁbroblasts and increase in collagen matrix deposition. This
ﬁbrogenic effect is not only limited to the retroperitoneum, but may
also involve pericardium, pleura, and lungs [21]. Other medications
reported as associated with RPF include -blockers, hydralazine
and phenacetin but whether there is a true causal relationship is
still debated [1,22,23].
Recently,  cases of RPF secondary to the use of biological agents
have been reported, especially with the use of inﬂiximab, a mono-
clonal antibody directed against tumor necrosis factor- (TNF-),
and etanercept, a soluble receptor that acts as a TNF- blocker
[24,25]. How these drugs, widely employed in the treatment of
rheumatic diseases, may  trigger a ﬁbrotic reaction in the retroperi-
toneum is still unclear, although it is well known that they may
trigger a number of autoimmune conditions.
Malignancies are often listed as potential causes of secondary
RPF. In most of these cases, RPF is the consequence of an exuberant
desmoplastic response of retroperitoneal metastases (e.g., carci-
noma of the prostate, breast, colon) or of a primary retroperitoneal
tumor (e.g., Hodgkin’s and non-Hodgkin lymphomas, inﬂammatory
myoﬁbroblastic tumour, well-differentiated liposarcoma scleros-
ing variant and various types of sarcomas) [26]. The only exception
are carcinoids, that are likely to induce RPF in the absence of metas-
tases, or primary localisations in the retroperitoneum, probably
through a mechanism mediated by serotonin or by the release of
proﬁbrogenic growth factors such as platelet-derived growth fac-
tor, insulin-like growth factors, epidermal growth factor and the
family of transforming growth factors  and  [27].
In case of infection-related RPF, the disease is usually sec-
ondary to the local spread of a contiguous infectious focus (e.g.,
spinal or paraspinal abscesses in patients with tuberculosis), or
to an immune response triggered by a remote infection. In addi-
tion to Mycobacterium tuberculosis, which has often been reported
as etiologic agent, actinomycosis or histoplasmosis can sometimes
represent the primary infections [28].
Other potential causes of RPF include radiotherapy, trauma,
major abdominal surgery, proliferative disorders such as
Erdheim–Chester disease, a rare form of non-Langerhans cell
histiocytosis, and other histiocytoses [29].
4. Pathology: gross and microscopic ﬁndingsIn terms of macroscopic ﬁndings the idiopathic and secondary
forms of RPF may  look similar. RPF appears as a hard and grayish
mass that inﬁltrates the retroperitoneal adipose tissue and does
not have a ﬁbrous capsule. In neoplastic forms the retroperitoneal
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asses appear irregular in morphology depending on the type of
umors.
The microscopic observation of idiopathic RPF samples reveals
he presence of two components: a ﬁbrous tissue and an inﬂamma-
ory inﬁltrate [30]. The ﬁbrous component consists of an abundant
atrix composed of type I collagen and a population of spindle-
haped cells characterized immuno-histochemically as ﬁbroblasts
nd myoﬁbroblasts (positive for vimentin and -smooth muscle
ctin, respectively). The ﬁbroblast population does not show any
ign of active proliferation (mitoses). The collagenous stroma con-
ains varying quantities of nerves and small blood vessels that
ften show a prominent perivascular hyalinisation. The inﬂamma-
ory component inﬁltrates variably the ﬁbrous tissue and consists
f lymphocytes, macrophages, plasma cells and rare eosinophils
rganized into perivascular and diffuse patterns (Fig. 1). In the
rst pattern, aggregated lymphocytes surround the small retroperi-
oneal vessels and tend to have a central core of B cells and a
eriphery of CD4+ and CD8+ T cells. In contrast, the diffuse pattern
s characterized by inﬂammatory inﬁltration of the narrow spaces
ithin the collagen bundles with T cells outnumbering B cells
10].
In IgG4-related RPF the microscopic ﬁndings are very similar to
hose of idiopathic RPF; IgG4-related RPF shows more commonly
bliterative phlebitis, a mild-to-moderate eosinophil inﬁltrate, and
brosis with a storiform pattern. As in idiopathic RPF, the inﬂam-
atory inﬁltrate is composed of T and B lymphocytes, whereas
 cells are typically organized in germinal centers and T cells are
istributed diffusely. Although IgG4-bearing plasma cells may  be
lso found in the inﬂammatory inﬁltrate of idiopathic RPF, what
s essential for the diagnosis of IgG4-RD is a ratio of IgG4-bearing
lasma cells to total IgG-bearing plasma cells higher than 30–50%
Fig. 1) [5].
The  secondary forms of RPF caused by malignancies are char-
cterized by the presence of neoplastic cells scattered into an
bundant ﬁbrous tissue; disruption or inﬁltration of neighboring
uscle and bone structures is commonly found. The inﬂammatory
nﬁltrate can be monoclonal in case of lymphomas and the pres-
nce of lipoblasts may  suggest the diagnosis of well-differentiated
iposarcomas with sclerosing and inﬂammatory features.
Finally,  Erdheim–Chester disease is characterized by varying
mounts of “foamy” histiocytes (consistently CD68KP1 positive and
egative for CD1a) in dense collagen tissue [29].
. Clinical features and laboratory tests
All the forms of RPF (i.e., idiopathic, secondary, and IgG4-
elated) have similar clinical manifestations, thus their clinical
resentation may  not be of help in the differential diagnosis.
At  disease onset, the patients often suffer from a dull and con-
tant side, back, or abdominal pain, which can become colic-like
hen the ureters are encased. Renal failure due to a bilateral
reteral obstruction is seen in about 42–95% of the cases; other, less
requent complications include: lower extremity edema and deep
ein thrombosis arising as a consequence of the chronic compres-
ion/obstruction of the lymphatic vessels and veins respectively,
crotal swelling, varicocoele or hydrocoele, resulting from the
nvolvement of the gonadal vessels, and constipation [31]. When
he thoracic aorta or the peri-aortic arteries are involved, patients
ay suffer from hoarseness, secondary to recurrent laryngeal nerve
aralysis, dry cough or upper limb claudication.
In most patients, systemic or constitutional symptoms are
resent and they include fatigue, low-grade fever, nausea, anorexia,
eight loss, and myalgia [1]. Inﬂammatory markers such as eryth-
ocyte sedimentation rate (ESR) and C-reactive protein (CRP) are
levated in more than half of the patients and do not help incine interne 36 (2015) 15–21 17
differentiating  idiopathic and secondary RPF [32]. The monitoring
of ESR and CRP levels is often useful to follow the clinical course of
the disease [2].
There  is a strong association between idiopathic RPF and
other autoimmune/inﬂammatory diseases, especially autoim-
mune thyroid diseases (e.g., Hashimoto’s and Riedel’s thyroiditis),
anti-neutrophil cytoplasmic antibody (ANCA)-positive glomeru-
lonephritis, rheumatoid arthritis, psoriasis and systemic lupus
erythematosus [2,12,13,16,32–34].
IgG4-related (systemic) disease is often diagnosed incidentally
through radiologic ﬁndings and, contrary to idiopathic RPF, usu-
ally shows a subacute course with no signiﬁcant elevation of
the inﬂammatory markers and absence of constitutional symp-
toms [5]. The disease ranges from organ-limited to multi-systemic
forms, where the clinical manifestations can be synchronous or
metachronous [5]. Unlike patients with idiopathic RPF, those with
IgG4-RD usually have a history of chronic allergic conditions (e.g.,
atopy, eczema, asthma and peripheral blood eosinophilia) and they
tend to develop tumour-like lesions, which may be responsible for
tumorous swellings of the affected organs [5].
Ureteral encasement and renal dysfunction are closely related
but, since an underlying glomerulonephritis can be present,
proteinuria and urinary sediment should always be checked. Micro-
scopic or macroscopic hematuria may  be found even in absence
of any renal parenchymal disease, probably as a result of ureteral
entrapment/injury.
Idiopathic RPF requires a detailed evaluation of autoimmune
tests. Antinuclear antibodies (ANAs) and anti-smooth-muscle anti-
bodies are the most frequently positive autoantibodies followed by
rheumatoid factor. The presence of these autoantibodies, although
non-organ speciﬁc and often positive at low titers, may  suggest
an autoimmune origin of the disease. ANCA have been identiﬁed in
cases associated with granulomatosis with polyangiitis (previously
Wegener’s disease) and microscopic polyangiitis while the pres-
ence of antibodies against thyroid microsome and thyroglobulin is
usually associated with an autoimmune thyroiditis, probably the
autoimmune disease most frequently associated with idiopathic
RPF [2,32].
One of the most important characteristics of IgG4-RD is the pres-
ence of high IgG4 serum levels [6]. Few data exist on serum IgG4
levels in patients with extra-pancreatic IgG4-RD. Most patients
have elevated serum IgG4 concentrations, but the range varies.
Published data reported that approximately 30% of patients have
normal serum IgG4 concentrations, despite the presence of classic
histopathological and immunohistochemical ﬁndings, including a
signiﬁcant inﬁltration of IgG4-bearing plasma cells [5].
Malignancies of the retroperitoneum cannot be identiﬁed by any
speciﬁc laboratory test but, when approaching a patient with a sus-
pected RPF, it is mandatory to perform an age-appropriate cancer
screening.
6. Imaging
Imaging studies play a key role in the diagnosis and manage-
ment of idiopathic RPF and can help classify RPF as idiopathic or
secondary.
Ultrasonography is usually the ﬁrst-line study performed at the
disease onset to assess the presence of hydronephrosis and aor-
tic dilatation/aneurysm; in a few cases, a hypo-echoic peri-aortic
tissue may  be disclosed.
Currently,  abdominal computed tomography (CT) and mag-
netic resonance imaging (MRI) are considered the imaging studies
of choice to diagnose idiopathic RPF [1,35]. On CT, it appears
as a homogeneous tissue, isodense to muscle, surrounding the
lower abdominal aorta and the iliac arteries, and often enveloping
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Fig. 1. Pathology of idiopathic retroperitoneal ﬁbrosis. A. Idiopathic retroperitoneal ﬁbrosis is a ﬁbro-inﬂammatory disorder whose main components are a dense ﬁbrous
tissue  with thick collagen bands (arrowhead) and an inﬂammatory inﬁltrate that is organized in a perivascular (arrow) or diffuse (asterisk) pattern. B. Especially within the
perivascular inﬂammatory aggregates, vasculitic images (arrow) are sometimes detectable. In a fraction of cases, there are signiﬁcant amounts of IgG4-positive plasma cells (C),
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eighboring structures such as the ureters that generally are dis-
laced medially [10].
Magnetic  resonance imaging may  provide a better deﬁnition of
PF against the surrounding tissues, mainly when fat-saturation
mages are used. Idiopathic Retroperitoneal ﬁbrosis on MRI  is hypo-
ntense in T1-weighted images; in T2-weighted images its intensity
s low in the quiescent phases of the disease and high in the active
tages when there is abundant tissue oedema and hypercellularity.
n a recent retrospective study, diffusion-weighted imaging (DWI)
eatures and signal intensity values at T2-weighted MRI  were eval-
ated for the differential diagnosis of benign RPF and plaque-like
etroperitoneal malignant neoplasms. The authors concluded that
WI  could contribute to differential diagnosis of chronic RPF and
alignant neoplasms with RPF morphology. Lesions in the malig-
ant group and active RPF group had similar enhancement patterns,
hile those in the chronic RPF group demonstrated weak enhance-
ent. Signal intensity values on T2-weighted images were not
seful for differentiating these conditions [36]. The administration
f contrast medium is ﬁrmly recommended in the active phase of
he disease when the mass enhances on CT and MRI  [37].
Nuclear  medicine is a useful complement to radiographic imag-
ng as it provides an easy visualisation of the almost entire body.
luorodeoxyglucose-positron emission tomography (FDG-PET) is a
echnique that assesses disease activity and is useful in diagnosis
nd monitoring. Speciﬁcally PET may  show abnormal FDG uptake
y the retroperitoneal mass in active disease whereas in later stages
t is usually negative. FDG-PET can also reveal active vasculitis in
ther vascular territories and it may  disclose other affected areas,
uch as those observed in IgG4-RD, or occult neoplastic or infectiousematoxylin-eosin. C and D. 3,3’-diaminobenzidine-revealed immunohistochemical
).
processes  which could potentially cause or be associated with RPF
[38,39].
Morphological aspects of RPF on CT or MRI  may  help the
physician to differentiate idiopathic from secondary forms. Idio-
pathic forms are usually characterized by plaque-like densities with
peripheral inﬁltration whereas the proliferation of secondary forms
is usually nodular and lobulated [40]. In terms of mass size, idio-
pathic RPF, unlike lymphomas and metastases, is usually located
distal to the kidney hilium, anteriorly and laterally to the aorta
that is not displaced forward, and the ureters are pushed medi-
ally. Cancers generally appear as ﬁbrous mass dislocating the psoas
muscles or destroying the bone whereas idiopathic RPF does not
include any of these features [41]. Localized lymphadenopathies
adjacent  to RPF occur in idiopathic forms but when they become
conﬂuent and tend to surround the large vessels they are likely to
be malignant.
Erdheim–Chester disease should be suspected when peri-aortic
ﬁbrosis is associated with symmetrical and bilateral peri-renal
ﬁbrosis [2]. The Fig. 2 shows representative CT images of idiopathic
RPF, RPF secondary to non-Hodgkin lymphoma and RPF secondary
to Erdheim–Chester disease.
When  imaging studies do not show typical ﬁndings of idiopathic
RPF, tissue biopsy is often required; biopsy may also be recom-
mended in patients refractory to conventional steroid therapy.
Multiple biopsy techniques have been used in sampling RPF, includ-
ing open, laparoscopic or transcaval retroperitoneal biopsy, and
ﬁne-needle aspiration. However, in malignant RPF, the metastatic
cells are usually dispersed so diffusely in the ﬁbrotic tissue that
multiple deep surgical biopsies are needed [40].
M.L. Urban et al. / La Revue de médecine interne 36 (2015) 15–21 19
Fig. 2. Representative abdominal contrast-enhanced computed tomographic (CT) scan of idiopathic and secondary retroperitoneal ﬁbrosis (RPF). The images show a case
of  non-Hodgkin lymphoma mimicking RPF; the muscle-isodense tissue encircles the abdominal aorta and displaces it anteriorly (A), a feature more common in malignant
than in idiopathic disease. Bilateral hydronephrosis due to ureteral encasement is also seen. The tissue extends caudally to involve both common iliac arteries (D), and tends
to  inﬁltrate the psoas muscles, a feature that is unusual in idiopathic RPF. The scans show a typical case of idiopathic RPF, where the tissue develops around the anterior
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nﬁltration is rare in idiopathic RPF.
. Therapy
The aims of treatment of idiopathic RPF are to induce regression
f the ﬁbro-inﬂammatory reaction, to relieve the obstruction of the
reters or other retroperitoneal structures, to switch off the acute-
hase reaction and its systemic manifestations, and to avoid disease
ecurrence.
In all cases of renal failure and severe bilateral hydronephro-
is, ureteral decompression should be promptly performed to avoid
ermanent kidney damage. If the “conservative” approach (ureteral
tents or nephrostomies followed by medical therapy) is inef-
ective, it becomes mandatory to perform surgical/laparoscopic
reterolysis.
Medical therapy should also be initiated as soon as it is pos-
ible. Induction therapy with the use of high doses of prednisone
1 mg/kg/day for the ﬁrst month) is the best option to curb dis-
ase activity. After one month of therapy, a re-evaluation of disease
ctivity (symptoms, ESR and CRP) together with a morphological
ssessment of the mass is recommended. If remission is obtained,
rednisone may  be progressively tapered to 5–10 mg daily within
–4 months, and then maintained for an additional 6–9 months.
hen a contraindication to glucocorticoid therapy is present, a
ood alternative may  be the use of tamoxifen. This drug seems
o have positive effects on ﬁbrosing disorders based on its antian-
iogenic properties and its capacity to down-regulate the release
f growth factors involved in ﬁbroblast proliferation and collagen
roduction [42]. In the only randomized controlled trial performed
n idiopathic RPF patients, 36 of 39 patients who  obtained remis-
ion after induction therapy with prednisone were randomised to
rednisone tapering or to switch to tamoxifen (0.5 mg/kg/day) for
n overall duration of 8 months. Relapses were more frequent in
he tamoxifen group, with the between-group difference in relapse
ates being signiﬁcant both at the end of treatment (month 8)
nd at 26 months follow-up [43]. Recently, tamoxifen has been
mployed as monotherapy in idiopathic RPF in a retrospective
tudy on 55 patients; the results showed response in terms of mass). RPF secondary to Erdheim–Chester disease; the retroperitoneal tissue diffusely
phrosis (C), and also extends to surround the common iliac arteries (F). Peri-renal
reduction in 71% of the patients at month 4 and 85% at month 8, and
conﬁrmed its good tolerability [44]. In summary, although proba-
bly inferior to prednisone in maintaining remission, tamoxifen can
be reserved to those patients who have contraindications to the use
of glucocorticoids.
The treatment of the refractory/relapsing forms of idio-
pathic RPF (resistant to glucocorticoid therapy or frequently
relapsing upon glucocorticoid tapering/withdrawal) is still a chal-
lenge. Several immunosuppressive drugs (e.g., mycophenolate
mofetil, azathioprine, methotrexate, cyclosporine, cyclophos-
phamide, tamoxifen) have been employed but so far there have
been only observational, uncontrolled clinical trials [43,45,46].
Low-dose prednisone plus methotrexate may represent an option
for the treatment of relapsing patients who  need a long-term
therapy, and so is probably mycophenolate mofetil, due to its
anti-inﬂammatory and antiﬁbrotic activity [45,47]. However, both
therapeutic approaches need to be investigated in prospective ran-
domized studies.
Recently there have been some reports of a successful use of
biologic agents in case of refractory idiopathic RPF. The agents
employed are rituximab, inﬂiximab (anti-TNF- monoclonal anti-
body), and tocilizumab (anti-interleukin-6 receptor antibody) but
the data are so scarce that no deﬁnitive conclusions can be drawn
[24,48,49].
Idiopathic RPF in the context of IgG4-RD tends to respond
promptly to 6–9 months of glucocorticoid therapy but in the refrac-
tory cases rituximab has been efﬁciently employed [5]. However,
IgG4-related and -unrelated RPF probably represent different ends
of the same disease spectrum; the degree of IgG4-plasma cell inﬁl-
tration is the main histological distinctive feature, but no clinical or
radiological differences are found [6]; thus, although studies com-
paring the outcome of these two  entities are lacking, it is likely that
they may  be treated with similar medical approaches.
Treatment of the secondary forms of RPF requires, when
possible, an approach based on the cause. Unfortunately, RPF
caused by untreatable cancers, trauma, major surgery, and
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adiotherapy, has no clear indications for systemic medical treat-
ent and might only draw beneﬁt from palliative surgical
pproaches. Malignant RPF carries a poor prognosis, with a mean
urvival of as little as 3–6 months. Retroperitoneal ﬁbrosis sec-
ndary to Erdheim–Chester disease also requires interventional
rocedures in order to relieve ureteral obstruction, followed by
peciﬁc medical therapies, which are now based on the use of
nterferon-, various immunosuppressive therapies and, in cases
earing the V600E mutation of the BRAF proto-oncogene, the BRAF
nhibitor vemurafenib.
.  Conclusions
Idiopathic RPF is a rare disorder, for which an early diagnosis
s warranted in order to promptly start systemic therapy and to
reat obstructive complications such as ureteral obstruction that
ay  lead to irreversible kidney damage. The exclusion of sec-
ndary forms of RPF is mandatory as the effect of the drugs usually
mployed in cases of idiopathic RPF, especially immunosuppressive
gents, may  worsen the prognosis of RPF secondary to malignan-
ies or infections. All patients with newly diagnosed RPF should
ndergo an age-appropriate cancer screening; with the aid of imag-
ng studies (abdominal CT and MRI, whole body PET-CT) and of
linical and laboratory features, a diagnosis of idiopathic or sec-
ndary RPF is usually possible. In doubtful case, a tissue biopsy
hould be performed.
Finally,  in the algorithm of the diagnostic approach for idio-
athic RPF, physicians should always keep in mind that the disease
ay be associated with other extra-retroperitoneal inﬂammatory
r autoimmune disorders.
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